Role of Biosimilars in Gastrointestinal Diseases

EP: 1.Indication and Practical Utilization of IV and Subcutaneous Biologics

EP: 2.Key Consideration and Concerns Around IV and Subcutaneous Biologic Use

EP: 3.Clinical Considerations for the Utilization of Intravenous vs. Subcutaneous Biologics

EP: 4.Key Patient Factors in Determining an Optimal Biologic Therapy

EP: 5.Incorporating Patient Perspectives When Determining a Route of Administration for Biologic Therapies

EP: 6.Future Predictions for Intravenous and Subcutaneous Biologics

EP: 7.Overall Experience With Intravenous Biologics

EP: 8.Clinical Insights With Subcutaneous Biologics

EP: 9.Innovations Associated With IV Biologics

EP: 10.Exciting Developments With Subcutaneous Biologics

EP: 11.Positioning Intravenous and Subcutaneous Biologics

EP: 12.Adherence With Intravenous Biologics

EP: 13.Billing With Intravenous and Subcutaneous Therapies

EP: 14.Evaluating Efficacy Between Intravenous and Subcutaneous Biologics

EP: 15.Cost Considerations With Intravenous and Subcutaneous Biologics

EP: 16.Patient Experience With Intravenous and Subcutaneous Therapies

Now Viewing

EP: 17.Role of Biosimilars in Gastrointestinal Diseases

EP: 18.Future Direction of Intravenous and Subcutaneous Biologics

EP: 19.K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies

Video content above is prompted by the following:

• How have the introduction of IV biosimilars impacted your treatment decisions? Do you see subQ biosimilars having a role in the future?